Mounjaro 17.5mg: Is This a Real Dose, and What Happens If You've Seen It?

You've seen '17.5mg Mounjaro' somewhere, here's what's actually going on

It happens more often than you'd think. Someone is a few months into treatment, things are going well at 15mg, and a search for 'what comes next' returns references to a 17.5mg dose. Or a seller online lists it as a product. The honest reaction to that isn't confusion, it's scepticism. A dose that sits outside the UK's licensed schedule for tirzepatide should raise immediate questions about where it's coming from.

Mounjaro (tirzepatide) is made by Eli Lilly and licensed in the UK as a once-weekly subcutaneous injection. Its approved strengths, confirmed in the prescribing information held on the electronic Medicines Compendium, are 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. The dose ladder climbs in 2.5mg increments and stops at 15mg. There is no 17.5mg pen in the authorised product range, not a trial dose, not a coming formulation, not a UK product under review. If a seller is listing one, you're looking at something that falls outside legitimate supply entirely.

The MHRA has repeatedly warned about fake weight-loss pens circulating online and via social media. Verifying any pharmacy on the GPhC register takes about thirty seconds and is the single most useful check you can do before purchasing any prescription weight-loss medicine.

Why the dose schedule is built the way it is

The titration structure isn't arbitrary. Treatment begins at 2.5mg not because that dose produces meaningful weight loss, but because it gives the body time to adjust to tirzepatide's mechanisms before higher exposures are introduced. Gastrointestinal side effects (nausea, bloating, changes to bowel habit) tend to be most noticeable when you start or when a dose increases, and the slow step-up is specifically designed to reduce that.

From 2.5mg, the prescriber typically increases in 2.5mg steps at approximately four-weekly intervals, subject to how you're tolerating the current dose. Not everyone needs to reach 15mg. Some people find 7.5mg or 10mg gives them the response they were hoping for, and their prescriber may choose to maintain at that level rather than continuing upward. The 7.5mg dose is a common maintenance point for that reason.

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants on 15mg tirzepatide achieved around 20–21% average body-weight reduction over 72 weeks. Those are the results that make the medicine what it is. The licensed ceiling of 15mg reflects the doses tested and approved; a 17.5mg figure would represent something untested in this context and unregulated in the UK.

If you're wondering how the earlier dose steps compare, the Mounjaro dose guide covers each rung of the schedule in detail.

What to do if you've been offered a dose that doesn't match the licensed range

Red flags tend to cluster. Sellers offering unlicensed doses, pens priced far below the market, or treatment dispensed without any clinical assessment are all signals to walk away. In 2025, enforcement teams seized approximately 20 million doses of illegally traded weight-loss medicines with a street value of around £45 million, including a raid on the first illicit UK site manufacturing counterfeit tirzepatide pens. Counterfeit pens have been found to contain insulin, a genuinely dangerous substitution.

If you've already been using a product whose dose doesn't match the licensed schedule, the right step is to speak to a healthcare professional promptly. You can also report suspect sellers directly via the MHRA's Yellow Card scheme, which handles both adverse reactions and suspected counterfeit products.

For anyone currently on a legitimate course of Mounjaro and wondering about what their next step looks like, the move from 5mg to 7.5mg is a good illustration of how the clinical titration process actually works. And if you're earlier in the process and considering whether to start, the free consultation is the right place to begin, a prescriber reviews your answers the same day, not an algorithm.

A note on cost context and what unlicensed products often signal

Eli Lilly raised Mounjaro's UK list price in September 2025, and typical private prices since then have ranged roughly £149–£375 per month depending on dose and provider. That context matters here: a listing priced noticeably below the lower end of that range, or offering a dose that doesn't exist on the licensed schedule, is almost always a signal that the supply chain is not legitimate.

For a prescription medicine, price is not the right test of quality. Genuinely supervised, licensed-supply treatment (reviewed by a real prescriber, dispensed by a verified pharmacy) is what keeps the process safe. The background on Mounjaro pricing in the UK explains the 2025 list-price change and what it means for private costs. It is also worth knowing that tirzepatide bodybuilding dosage queries sometimes lead people toward unregulated sellers, so anyone researching the medicine in that context should take the same care over supply-chain legitimacy. For a broader look at all your options, the weight-loss treatment overview sets out what's licensed and available.